Genomic Health→Exact Sciences
Acquisition · Cash + Stock · EXAS · announced Jul 29, 2019
Announced
Jul 29, 2019
Closed
Nov 8, 2019
Economics
Cash + Stock()
Pre-deal · pre-deal mark: 2019, year precision · rounding grid ±$100M · Exact Sciences 8-K filing, SEC EDGAR — Genomic Health acquisition
~$2.8B total consideration
Target
Genomic Health
Precision Medicine · Diagnostic / genomic
HQ Redwood City, CA · Founded 2000
Oncotype DX genomic tests for breast, colon, and prostate cancer — used to guide chemotherapy decisions for early-stage breast cancer
- Exact Sciences newsroom - press release (Jul 29, 2019)
- SEC EDGAR - merger proxy filing
Acquirer
Exact Sciences (EXAS)
Precision Medicine
HQ Madison, WI
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Combined Cologuard (colorectal) with Oncotype DX (breast cancer) to create leading global cancer diagnostics company — Oncotype DX guides chemotherapy decisions for ~50% of early-stage breast cancer patients
Evidence ladder
Secondary (press / IR)
Exact Sciences newsroom (Jul 29, 2019)
Primary (regulatory / filing)
SEC merger proxy
SEC EDGAR filings (ticker locator)
Limitations
- ~$2.8B total consideration
- Pre-deal valuation sourced from: Exact Sciences 8-K filing, SEC EDGAR — Genomic Health acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Precision Medicine
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| GRAIL | Illumina | Sep 21, 2020 | same evidence class | |
| Foundation Medicine | Roche | Jun 19, 2018 | same evidence class | |
| Flatiron Health | Roche | Jan 8, 2018 | value band |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Varian Medical Systems | Siemens Healthineers | Aug 2, 2020 |
Other verified deals by Exact Sciences
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| PreventionGenetics | Exact Sciences | Jan 9, 2022 | Diagnostics | |
| Thrive Earlier Detection | Exact Sciences | Oct 27, 2020 | Diagnostics |
Patient empowerment context
Empowerment context — Genomic Health
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Not recommended genetic testing (NCCN: almost all should) (Company / product site)37%cited HLTH 2022Mapping source →
- Presented with clinical trial as treatment option (Press release)1 in 5cited HLTH 2022Mapping source →
- No survivorship care plan after active treatment (Company / product site)54%cited HLTH 2022Mapping source →
Other curated mappings on these gaps: Biotheranostics, Endomagnetics, Foundation Medicine, Flatiron Health
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.